OOIR: Observatory of International Research

Papers

(The H4-Index of Osteoporosis International is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Dual-energy x-ray absorptiometry scanner mismatch in follow-up bone mineral density testing	721
Comment on “Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer”: Waxing-Waning Serum Calcium following Denosumab use in a patient with Polyostotic Paget’s Disease of Bone	282
RE: “Race/ethnic differences in trabecular bone score in mid-life women: the Study of Women’s Health Across the Nation (SWAN)”	90
Response to letter, re. “Comparison of fracture risk between type 1 and type 2 diabetes: a comprehensive real-world data”	85
Incident peptic ulcers and concomitant treatment of direct oral anticoagulants and oral bisphosphonates—a real-world cohort study	81
Mineral-rich water consumption as a non-pharmacological intervention for early menopausal bone mineral density preservation and reduction of long-term fracture risk: comment on Billington et al. Osteo	76
A promising strategy for the diagnosis, treatment, and prevention of osteoporosis (EMS strategy)	75
One versus 2 years of alendronate following denosumab: the CARD extension	60
Correction to: Author response to the comments on our article Relatively low and moderate pre-fracture serum 25-hydroxyvitamin D levels associated with the highest survival in elderly hip fracture pat	56
The clinical trial landscape of anti-RANKL agents for osteoporosis: current status and future directions	54
The association between blood cadmium levels and bone mineral density in U.S. adolescents aged 12–19 years	52
Impact of the guidance on fracture Liaison Services and the introduction of a new fee for secondary fracture prevention in Japan: Implementation of secondary fracture prevention during hospitalization	46
The effects of β-carotene on osteoporosis: a systematic review and meta-analysis of observational studies	46
RETRACTED ARTICLE: Evaluation of bone mineral density (BMD) and trabecular bone score (TBS) in pheochromocytoma and paraganglioma; a multi-centric case–control study from India	45
Changes in spinal sagittal balance after a new osteoporotic vertebral compression fracture	40
Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk	40
Trajectories of oral bisphosphonate use after hip fractures: a population-based cohort study	39
Epidemiology of pelvic and acetabular fractures in the USA from 2007 to 2014	39
Scaffolds: a biomaterial engineering in targeted drug delivery for osteoporosis	37
The incidence of subsequent contralateral hip fracture and factors associated with increased risk: the IMPACT Contralateral Fracture Study	36
Follicle-stimulating hormone is associated with low bone mass in postmenopausal women	35
The link between osteoporosis and cardiovascular diseases: a review of shared mechanisms, risk factors, and therapeutic approaches	34
Association between body mass index, bone bending strength, and BMD in young sedentary women	34
Return on investment of fracture liaison services: a systematic review and analysis	34
Artificial intelligence insights into osteoporosis: comment	33

Association between dental diseases and oral hygiene care and the risk of vertebral fracture: a nationwide cohort study	32
Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019–2023	32
Author response to: Comment from Dongdong Cao, et al. on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nati	32
Bisphosphonate drug holidays in osteoporosis according to fracture risk profile	31
Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis	29
An LRP6 mutation (Arg360His) associated with low bone mineral density but not cardiovascular events in a Caucasian family	29
Patients not taking a previously prescribed bone active medication now prescribed medication through Ontario FLS	29